Teva Pharmaceuticals announced today that it received European marketing authorization for its Seffalair and BroPair Spiromax inhalers.
Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) received approval as a maintenance treatment for asthma in adults and adolescents aged 12 years and older, according to a news release.
The indication is as a regular treatment for asthma for cases not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 agonists.
Teva said the launch of the inhalers, which is initially planned for Portugal, Switzerland, Spain and the UK, offers another asthma treatment with a product that has been well received by healthcare professionals and patients since the launch of the DuoResp Spiromax.
“We are excited about the European approval of Seffalair Spiromax and BroPair Spiromax, as an important goal of our respiratory franchise is to bring new treatment options to healthcare professionals who support people living with long-term conditions such as asthma,” Paul Blonk, head of Teva Respiratory Europe, said in the release. “We want to empower patients to effectively manage their condition through the medicines we provide, whilst also offering cost-effective treatments to healthcare systems.”